Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This Phase II trial is testing a combination of three drugs—zanidatamab, pembrolizumab, and chemotherapy—in 80 people with advanced stomach or esophageal cancer that has spread and tests positive for HER2 and PD-L1. The goal is to see if this triple therapy can keep the cancer fr…

This study tests a combination of two drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced or metastatic penile cancer that cannot be cured by surgery. The goal is to see if the drugs shrink tumors and help patients live longer. About 25 men will tak…

This study tests whether giving the drug cemiplimab before lymph node surgery can prevent Merkel cell carcinoma from spreading to nearby lymph nodes. About 135 adults with early-stage cancer will receive either the drug or a placebo before their scheduled biopsy. The goal is to s…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This phase 2 trial is testing the drug cemiplimab as a first-line treatment for people with advanced basal cell carcinoma who have not received prior therapy. The study will enroll 34 participants and measure how many patients see their tumors shrink or disappear after six months…

This study is for people with advanced liver cancer who are starting a combination of two drugs (atezolizumab and bevacizumab). It will test if adding a procedure called TIPS (which places a small tube in the liver to improve blood flow) can help keep the liver working better for…

This phase 2 trial tests a combination of two drugs—futibatinib (a daily pill) and tislelizumab (an IV immunotherapy)—in adults with advanced colorectal cancer. The goal is to see if the combo can shrink tumors and to identify biomarkers that predict response. About 33 people wil…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This Phase II trial tests whether combining fruquintinib (a targeted therapy) with tislelizumab (an immunotherapy) can help people with a specific type of advanced colorectal cancer that has not spread to the liver. The study will enroll 140 participants whose tumors are microsat…

This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participant…

This study is watching how lung cancer patients do when they get the drug tislelizumab in normal doctor visits, not in a strict research setting. About 240 people with small cell or non-small cell lung cancer will take part. The goal is to see how long they live, how the drug aff…

This registry is collecting information from up to 9,000 people in Germany with sarcoma or carcinosarcoma. Researchers will track how often different subtypes occur, how they progress, and what treatments patients receive. The goal is to better understand these rare cancers and i…